Novo Nordisk Gains Momentum with US Pill Approval

28 days ago

Natalya Kenny Javich

"Yes, it is a very nice day for the company. The ticker is NVO. Shares are up by 7.3%. At one point, shares jumped by 10% which was the biggest jump since August 2023. Of course, it came after the company said that it won an approval to sell a pill version of its Begoi drug in the US. The company will start selling it here starting from January and analysts were really excited about this news. They say it gives the company a really big tailwind especially as competition kind of is going to be more severe for the market."

Novo Nordisk (NVO) experienced a significant intraday rally, boosted by regulatory approval to introduce a pill version of its drug in the US, with sales set to begin in January. Analysts view this approval as a tailwind, particularly important given increasing competition.

Related Stocks